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Intestinal Permeability and Microbial Dysbiosis in Acute Coronary
Syndrome (MIACS study)
By
Tarik Z. Alhmoud
MD, University of Jordan, 2007
MS, University of New Mexico, 2017
ABSTRACT
Background: Acute Coronary Syndrome (ACS) is a leading cause of morbidity
and mortality. Metabolic syndrome and obesity are major risk factors for
atherosclerosis and ACS. Dysbiosis plays an important role in metabolic
syndrome and obesity. Studies show a markedly increased risk of heart attacks
in patients with high levels of the pro-atherogenic metabolite trimethylamine-NOxide (TMAO). TMAO is produced by the intestinal microbial flora through
metabolism of dietary phospholipids; Gram-negative bacteria (Phylum
Proteobacteria) is the major source of TMAO metabolism. Patients with obesity
and metabolic syndrome have a defective intestinal tight-junctional (TJ) barrier,
which allows paracellular permeation of luminal antigens such as
lipopolysaccharides (LPS; endotoxins); leading to endotoxemia. Endotoxins are
also associated with increased risk of atherosclerosis and cardiovascular
disease. We aim to study the hypothesis that patients with ACS have dysbiosis,
including higher proportion of Gram-negative bacterial species capable of
v

producing the pro-atherogenic metabolite TMAO, and test if dysbiosis in ACS
patients is associated with increased intestinal permeability and endotoxemia.
Methods: This is a prospective case-control study conducted at a single
university hospital. We enrolled ACS patients (within 72 hours of acute cardiac
events) and healthy controls. Relevant clinical and demographic data were
collected. Stool microbiome composition was examined using the 16S ribosomal
RNA (Illumina) method to identify microbiota taxonomic genera. LPS serum level
was measured by an ELISA-based method. The intestinal TJ barrier function was
evaluated using lactulose-to-mannitol urinary excretion ratio (L/M ratio). Serum
TMAO was measured using a mass spectrometry.
Results: We enrolled 19 patients and 19 controls. ACS patients had increased
relative abundance of Gammaproteobacteria and Proteobacteria compared to
healthy controls, with mean proportions of 1.8 ± 3.0 vs 0.2 ± 0.4 % (P = .04) and
4.1 ± 3.8 vs 2.1 ± 1.7% (P=.056), respectively. L/M-ratio was three times higher
in ACS patients compared to healthy controls (.06 ± .07 vs .023 ± .02, P = .014).
There was no difference in the mean serum LPS or TMAO levels.
Conclusion: ACS patients have dysbiosis and increased intestinal permeability.
Further studies are required to find the role of dysbiosis in acute cardiac events.
Keywords: dysbiosis, Intestinal tight Junctional barrier, Intestinal permeability,
Proteobacteria, Gammaproteobacteria, TMAO, Endotoxemia, LPS, Endotoxins,
Acute Coronary Syndrome and myocardial infarction.
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Chapter One
Introduction
Acute Coronary Syndrome (ACS; heart attacks) is a leading cause of morbidity
and mortality in developed countries, and is growing in prevalence in developing
countries; according to the World Health Organization (WHO) fact sheets (1).
Metabolic syndrome and obesity—both major risk factors for atherosclerosis and
ACS—are emerging as a worldwide pandemic (2). Metabolic syndrome is
defined [by the National Cholesterol Education Program (NCEP), Adult
Treatment Panel III (ATP III)] as a cluster of: central obesity, hyperglycemia,
hypertriglyceridemia, low high-density lipoprotein (HDL) levels and hypertension-three out of five criteria are required to confirm diagnosis (3). WHO requires
evidence of Insulin Resistance (such as impaired glucose tolerance or Diabetes
Mellitus type II (DMII)) to fulfill the definition of metabolic syndrome (4). Despite
the increasing prevalence of ACS, obesity and metabolic syndrome, our
understanding of the underlying pathophysiology and what links these conditions
is still evolving.
The Intestinal Microbiome
In the twenty-first century, technology is advancing gene sequencing and it’s
bioinformatic applications, this has transformed microbiome genomics and
molecular biology sciences. Next Generation Sequencing (NGS) platform allows
detailed study of biological samples (such as human feces) in less than 24
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hours. Investigators can run tens of samples simultaneously with immediate
bacterial DNA/RNA sequencing and analysis of large amounts of produced data.
Prior to the availability of gene sequencing, microbiologists and scientist used
bacterial cultures to identify bacterial species in a biological specimen; however,
most organisms could not be cultured, and the process was costly and timeconsuming (5).
The wide use of NGS and metagenomics, allowed rapid advancement of our
understanding of the intestinal microbiome composition. Metabolomics allow us
to study the function of the microbiome. The number of publications about the
microbiome has exponentially increased over the last decade (6). The intestinal
microbiome has been linked to many diseases including atherosclerosis, airways
diseases, brain disease and cancer among others (7, 8), and multiple studies in
this area has shed light on the important role of intestinal microbial flora in
metabolic syndrome and obesity (4, 5). The term intestinal microbiota refers to
micro-organisms living in the human intestine, this include bacteria, archaea,
viruses and fungi. The term microbiome is used to describe the community of
microorganisms living in a certain habitat and the surrounding environment as
well. We will use the term intestinal microbiota to refer to the intestinal bacteria in
this study.
The intestinal microbiome contains hundreds of bacterial species (in older
studies) (9); the number increased to thousands with the new bacterial gene
sequencing methods. Over the last decade, the intestinal microbiome is
increasingly recognized as an organ that serves different functions, most
2

importantly influencing our metabolic function and immune homeostasis (10, 11).
The human genome contains about 20,000 genes (12) and the intestinal
microbiome has ~150 times more genes than the human genome (13). It is not
surprising that alterations in the intestinal microbiome (dysbiosis) are associated
with multiple diseases such as metabolic syndrome and obesity (14, 15).
Intestinal microbiota are composed of more than one thousand species of
bacteria. Several major bacterial Phyla make up the entire intestinal microbiota in
humans: Bacteroidetes, Firmicutes and minorities of Actinomyces;
Proteobacteria and Verrucomicrobia. The intestinal microbiota varies widely
between individuals and in the same individual at different times (16, 17).
However, the function of intestinal microbiota is very similar in different people,
based on the shot-gun metagenomic studies, predicting the enzymatic and
metabolic pathways of different organisms(13).
Terms and Definitions
Figure1. below include definitions for many technical terms used in the
microbiome field (6, 18, 19).
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Definitions
Microbiota
Organisms living in a certain environment such as a body organ. Microbiota
include bacteria, archaea, viruses and fungi
Microbiome
Community of organisms (microbiota) and the surrounding environment
Metagenome
Sum of genomes and genes of all organisms
Metabolome
Metabolites produced by microbiota and host cells in a certain environment, this
include proteins, lipids, saccharides etc.
Metatranscriptome
Indicates the active genes that are transcribed by microbiota in a certain
environment; a collective profiling of the mRNA from all organisms
Prebiotic
Nutrients that promote growth of healthy microbiota
Probiotic
Living microorganism or consortium of microorganisms that confers health
benefits to the host, as a supplement
Next-generation sequencing (NGS)
Also known as High Throughput Sequencing; is a method for fast and costeffective DNA and/or RNA sequencing. NGS is used to study Eukaryotic and
Prokaryotic cells
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Figure 1. (cont.)
Shot-gun sequencing
Is a special case of High Throughput Sequencing, where long strands of DNA
are sequenced with the goal for whole genome analysis
16S rRNA gene
Is part of the Prokaryotic 30S ribosome subunit. The 16S rRNA gene is well
preserved and is used to identify specific bacterial species or genera. Some
bacterial strains have multiple 16S rRNA genes
Operational Taxonomic Unit (OTU)
A classification system based on the similarity of a taxonomic reference gene
(e.g 16S rRNA). Organisms with greater than 97% similarity are classified as a
unique OTU
Alpha Diversity
Alpha diversity or local diversity depend on the number of microbial species in
each sample, and the evenness of species
Beta Diversity
A measure of diversity between different samples (how many species are shared
between different samples)
Chao1 index
Is a measure of Alpha diversity, with focus on richness of microorganisms in a
sample
Principal Component Analysis PCA
A complex statistical method used in data analysis. It is useful in visualizing
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Figure 1. (cont.)
distance and relatedness between different populations and is commonly used in
genetics. The first component (first axis) account for the highest variability in
data, in comparison to other components (second and third axes)
Figure1. Definitions and technical terms used in the microbiome field

Intestinal Tight Junctional (TJ) Barrier
Small and large intestines are key organs for absorption of nutrients, water and
minerals. With a length of 15 feet (on average) and a large surface area [more
than 40 square meters and up to 300 square meters in older studies] (20). Most
of the human microbiota are present in the intestines, the number of bacterial
cells exceeds the number of human cells [1-10 times higher] (21). Inside human
intestines live trillions of bacteria; where the body is exposed to numerous
bacterial and dietary antigens, and potentially harmful substances. We are
separated from the outside world by an intestinal epithelial monolayer (compared
to the keratinized, thick skin epidermis). Intestinal epithelial cells are held
together by tight junctions; which form a barrier between cells, often referred to
as the intestinal tight junctional (TJ) barrier. TJs act as a physical and functional
barrier against penetration of harmful substances and bacterial antigens in the
intestinal lumen.

Defective Intestinal Tight Junctional Barrier
Patients with diseases affecting the small and/or large intestines often have a
defective intestinal tight junctional barrier, which leads to an increased intestinal
permeability (leaky gut). Examples of such conditions include celiac disease,
6

ulcerative colitis and Crohn’s disease (22). These individuals are at a higher risk
for cardiovascular complications (23). Moreover, defective intestinal tight
junctional (TJ) barrier with increased intestinal permeability, also occurs in many
systemic diseases, such as alcoholic and non-alcoholic steatohepatitis, obesity,
DMII and metabolic syndrome. Paracellular permeation of luminal antigens from
the intestinal lumen to the blood stream, appears to be an important pathogenic
factor in these conditions(24-26).

Lipopolysaccharides (LPS; Endotoxins)
Lipopolysaccharides (LPSs; endotoxins) are a major component of Gramnegative bacteria outer-membrane structure. In the presence of a defective
intestinal TJ barrier, harmful bacterial antigens such as endotoxins translocate to
the blood stream resulting in endotoxemia (27). Studies from our lab have shown
that LPS causes an increase in intestinal tight junction permeability in vitro and in
vivo (28).
Endotoxins are associated with increased risk of atherosclerosis and
cardiovascular events; subjects with high levels of endotoxins face a threefold
increased risk of developing atherosclerosis (29). The mechanism may include
direct damage to endothelial cells, which stimulate macrophage transformation
into foam cells; promoting atherosclerosis (30). The Endotoxin molecules bind
Toll-Like Receptor-4 (TLR-4), which is present in intestinal, immune and
endothelial cells, and form a receptor cluster with the Cluster of Differentiation-14
(CD14). TLR4 polymorphism confers reduced risk of atherosclerosis (31). CD14
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promoter polymorphism is a risk factor for ACS and atheromatous plaque
vulnerability (32). Investigators detected Proteobacteria (pathogenic Gramnegative bacteria) in atherosclerotic plaques (from endarterectomies) (33), and
blood levels of Proteobacteria DNA was associated with increased risk of cardiac
events (Odds ratio 1.56, 95%CI 1.12–2.15) (34).

Trimethylamine-N-Oxide (TMAO)
Intestinal microbiota are not inert organisms or bystanders; they play an
important role in metabolism. Metabolites produced by the intestinal microbiota
affect human health and diseases, of which TMAO is an important example.
Dietary phospholipids such as phosphatidylcholine and L-carnitine are
metabolized by intestinal bacteria to trimethylamine (TMA), subsequently TMA is
absorbed and converted into TMAO in the liver (by hepatic ﬂavin
monooxygenases 3 (FMO3)) (35, 36). Recent studies revealed an association
between trimethylamine-N-Oxide (TMAO) and risk for cardiovascular events (36,
37). In a large study (n = 4,007) elevated baseline TMAO plasma level was
associated with increased risk of major cardiovascular event (hazard ratio of
2.54) after three years of follow-up (37). In animal studies, TMAO’s
proatherogenic effect was visible by inducing atherosclerosis (38). In addition,
high TMAO blood levels were associated with higher odds of newly diagnosed
DMII (39). Phylum Proteobacteria is the major source of TMAO metabolism in
humans (40).
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Aims of the Study
It is known that TMAO, and endotoxemia (with underlying defective intestinal TJ
barrier) are risk factors for future ACS events. Intestinal Microbiota-Proteobacteria in particular--is the primary source of TMAO and endotoxins. The
intestinal microbiota composition, during or shortly after an acute cardiac event
(ACS) remains unclear. We aim to study the hypothesis that patients with ACS
have dysbiosis, including higher proportion of Gram-negative bacterial species
(Proteobacteria), which contribute to the production of the pro-atherogenic
metabolite TMAO. We aim to assess the intestinal TJ barrier function and serum
endotoxin levels shortly after acute cardiac events.

9

Chapter Two
Material and Methods
This is a prospective case-control study performed in a single tertiary center;
University of New Mexico Hospital. The study was approved by a UNM
Institutional Review Board (IRB) committee with a protocol number 13-625. The
study was conducted between March 11th, 2014 and November 30th ,2016.

Inclusion Criteria
Inclusion Criteria for Cases
Patients admitted to UNM Hospital cardiology service with Acute Coronary
Syndrome. We used the definition of ACS as described by the American Heart
Association:
A-STEMI: diagnosis is made by clinical symptoms (chest pain at rest) with
ST elevation >1mm in two contiguous EKG leads, or new LBBB (Left bundle
branch block) ± troponin-I > 0.12 ng/ml.
B-NSTEMI: This is defined by one of the following criteria (with elevated
troponin level): 1. Resting chest pain (angina) >20minutes in duration 2. New
onset angina <2 months, 3. Increasing angina in frequency/intensity or duration
and elevated cardiac markers; troponin > 0.12 ng/ml.
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C-Unstable Angina: 1. Resting angina >20minutes in duration 2. New
onset angina <2 months, 3. Increasing angina in frequency/intensity or duration.
Cardiac biomarkers are normal in these patients.
All patients were recruited in the study within 72 hours of admission, and after
Coronary Angiography and Percutaneous Coronary Intervention (PCI) were
completed.

Inclusion Criteria for Healthy Controls
Subjects in this group had normal body mass index (18.5 < BMI < 24.9), no
history of hypertension, diabetes or dyslipidemia, no prior heart attacks or
strokes, no tobacco use and no antibiotic use within three months prior to
enrollment.

Exclusion Criteria
•

Age less than19 years.

•

Pregnant women (pregnancy test verification for women in child-bearing
age).

•

Prisoners.

•

Adults unable to consent.

•

Sick patients including:

I.

Glomerular filtration rate (GFR) less than 60 (abnormal kidney function).

II.

Cardiac Ejection fraction (EF) < 45% (for the intestinal permeability test).
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III.

Patients requiring pressors including but not limited to dopamine or

norepinephrine.
IV.

Patients who received thrombolytics like tissue plasminogen activator.

V.

Patients requiring care in the Intensive Care Unit (ICU).

VI.

Patients requiring an intra-aortic balloon pumps (IABP).

VII.

Patient requiring a Coronary Artery Bypass Surgery (CABG).

VIII.

Patients requiring a trans-venous pacemaker.

Recruitment
All patients were screened for eligibility by a physician investigator. Healthy
controls (matched to cases by age and sex) were enrolled from a UNM Clinical
and Translational Science Center (CTSC) volunteer list. All subjects were offered
the opportunity to participate in the study by one of the study team members.
Subjects were enrolled after obtaining an informed consent. Each subject
provided blood and stool samples. Urine samples were collected for some of the
patients after a delayed approval by UNM institutional IRB. All samples were
frozen at -80º C until usage. Relevant clinical and demographic data were
documented.

Study Endpoints
The primary end point of the study is the relative abundance of intestinal
Proteobacteria in ACS patients compared to healthy controls. Secondary end
12

points include serum endotoxin and TMAO levels and assessment of the
intestinal TJ barrier function using the lactulose/mannitol urine excretion test.

Statistics
Sample size was calculated to achieve a statistical power >80%, and a level of
significance; α = .05 for different end points of the study.

Intestinal Microbiota Data Statistics
16S rRNA data was analyzed to detect alteration of the relative abundance of the
four-major intestinal microbial Phyla; including the phylum Proteobacteria (which
includes pathogenic Gram-negative bacteria). Our hypothesis is that one out of
the four major bacterial phyla (Proteobacteria) will be more abundant in ACS
patients compared to healthy controls. A non-parametric t-test (Satterthwaite
test) was used to compare the proportion of Proteobacteria in ACS patients
versus controls (due to unequal variance in data).
Physiologically, Proteobacteria makes up ~ 5-8% of the human microbiome; to
detect a 30% increase in this phylum in the ACS patient group, and to achieve a
power of > .8 and α of 0.05, eighteen (18) subjects are required in each group.
We anticipated that about 20-25% of subjects would not provide all the required
samples; therefore, we planned to recruit 25 subjects per group.
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How results were interpreted
The intestinal microbiota composition was displayed as relative abundance of
different intestinal bacteria at the Phylum, Class, Order, Family and Genus
levels. At each level, results were displayed using Bar-Charts to identify the
microbiota taxonomic phyla and genera. A bioinformatics team (Los Alamos
National Labs) helped analyze16S rRNA data by providing various Alpha
Diversity, Beta Diversity and Principal Component Analyses. It should be noted
that our sample size might not be adequate to detect all differences at the Genus
level.

Endotoxin and Intestinal Permeability Data Statistics
Sample size was calculated to achieve statistical power (>80%) and a level of
significance α = .05. Standard unpaired t-test used to compare the endotoxin
levels between ACS patients and controls, we predicted the mean serum LPS to
be at least 100% higher in ACS patients compared to controls, 18 subjects per
group are required to detect this effect size; based on preliminary results from
our alcoholic hepatitis (AH) study, the serum LPS level in AH patients was 420 ±
50.3 vs 18.9 ± 8.8 in healthy controls.
For the intestinal permeability test, we used the Mann-Whitney-Wilcoxon
nonparametric test as the data was not normally distributed. To detect a 100%
increase in intestinal permeability in the ACS group compared to the control
group; 17 patients per groups are required, based on our prior alcoholic hepatitis
study the lactulose to mannitol ratio in patients compared to controls was .23 ±
14

.08 vs .02 ± .003; we didn’t expect the same degree of increased intestinal
permeability in ACS patients.

How Results Were Interpreted
These studies are intended to determine the intestinal barrier function in patients
with ACS and healthy controls. The studies are expected to show that ACS
patients have an abnormal intestinal TJ barrier function with an increased
intestinal permeability to the paracellular marker lactulose. Lactulose to mannitol
ratio (L/M ratio) is a well-validated marker for intestinal permeability; L/M ratio is
expected to be higher in ACS patients compared to health controls. The results
will show the mean increase in L/M ratio and the proportion of ACS subjects who
have increased intestinal permeability. Similar approach will be used for serum
endotoxin levels, the results are intended to show the difference in endotoxin
levels between the two groups and what proportion of ACS patients have
increased endotoxin levels.

Intestinal Microbiota Sequencing and Analysis
DNA Extraction
DNA extraction from stool samples was performed using the ZR Fungal/Bacterial
Miniprep Kit (Zymo D6005). Approximately 150mg stool was homogenized in a
bead bashing tube at 6 m/s for 60 seconds on the MP Bio FastPrep 24
homogenizer. Homogenized stool samples were then processed per the

15

miniprep kit protocol. Extracted DNA was filtered using Spin-X Centrifuge Tube
filters (Costar 8160) prior to quantification.

DNA Sequencing
MetaVx™ Mammalian Library Preparation and Illumina MiSeq Sequencing Next
generation sequencing library preparations and Illumina MiSeq sequencing were
conducted at GENEWIZ, LLC. (South Plainfield, NJ, USA. DNA samples were
quantified using a Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) and DNA
quality was checked on a 0.6% agarose gel. Sequencing library was constructed
using a MetaVx™ Mammalian Library Preparation kit (GENEWIZ, LLC., South
Plainfield, NJ, USA). Briefly, 50 ng DNA was used to generate amplicons that
cover V3 and V4 hypervariable regions of bacteria and Archaea16S rDNA.
Indexed adapters were added to the ends of the 16S rDNA amplicons by limited
cycle PCR. Sequencing libraries were validated using an Agilent 4200
TapeStation system (Agilent Technologies, Palo Alto, CA, USA), and quantified
by Qubit and real time PCR (Applied Biosystems, Carlsbad, CA, USA). DNA
libraries were multiplexed and loaded on an Illumina MiSeq instrument according
to manufacturer’s instructions (Illumina, San Diego, CA, USA). Sequencing was
performed using a 2x250 paired-end (PE) configuration; image analysis and base
calling were conducted by the MiSeq Control Software (MCS) on the MiSeq
instrument.
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16S rRNA Analysis
Sequence analysis by QIIME pipeline. The 38 stool samples were processed
through QIIME analysis pipeline (v1.9.1, Caporaso et al 2010a). Raw paired-end
Illumina® fastq files were merged, de-multiplexed, quality filtered (-q 19 –p 0.5 –n
1) and resulted in 4,821,145 filtered sequencing reads. OTUs (operational
taxonomic units) were assigned using an open-reference OTU picking protocol,
where UCLUST (Edgar 2010) was applied to search sequences against a subset
of the Greengenes database (DeSantis et al 2006) filtered at 97% identity. Reads
were assigned to OTUs based on their best hit to this database at greater than or
equal to 94% sequence identity. Reads that did not match a reference sequence
were clustered by UCLUST to assign novel OTUs. The OTUs were further
filtered at minimum OTU abundance 2 (in number of sequences) to retain the
OTU. The cluster centroid for each OTU was chosen as the OTU representative
sequence. OTU representative sequences were then classified taxonomically
using the Greengenes taxonomy string by the best matching Greengenes 16S
rRNA sequence. In addition, OTU representative sequences were aligned using
PyNAST (Caporaso et al 2010b) against a template alignment of the Greengenes
database and phylogenetic trees were constructed using FastTree (Price et al
2010). The alpha-diversity estimates, beta-diversity estimates, taxonomy
summary table, group comparison were performed within QIIME using
“core_diversity_analyses.py” script with even subsampling at minimum 1,000
sequences per sample (41-45).
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Measurement of serum Endotoxin, Intestinal Permeability and
TMAO Levels
A 20-ml sample of peripheral blood was collected from each participant by
venipuncture. Serum level of endotoxin (LPS) was measured using a
Chromogenic Limulus Amoebocyte Lysate Quantification kit (Thermoscientific88282, IL, USA).
Assessment of Intestinal Permeability: After an overnight fast (8 hours), all
participants drank a 50-ml aqueous solution containing 2 gm mannitol and 5 gm
lactulose. Following ingestion, urine was collected for 5 h. Participants were not
allowed to consume food but were allowed to drink water during the 5 h urine
collection period. At the end of the collection period, the total urine volume was
recorded, and 20 ml of the urine was used for processing. The concentration of
mannitol and lactulose present in the urine was determined by an enzyme-based
assay (Megazyme, Ireland) and quantified by spectrophotometry. Results were
calculated as a ratio of lactulose to mannitol excreted in urine (46, 47). Serum
TMAO levels was measured using Liquid Chromatography Mass Spectrometry
(Cleveland Heart labs, Ohio, USA).
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Chapter Three
Results
Subject Characteristics
Nineteen ACS patients and similar number of healthy controls were recruited.
ACS patients were slightly older than healthy controls (mean age difference of
five years). ACS patients were overweight (mean BMI of 28.3) with a 4-point
higher Body Mass Index (BMI) than healthy controls. Patient characteristics at
baseline are shown in Table 1.
Table1. Baseline Characteristics of patients and healthy controls
Characteristic

ACS group
(n=19)

Control group
(n=19)

P-value

Age (mean ± SD)

54.4 ± 2.2

49 ± 1.6

.07

Gender M (n, %)

14 (74)

13 (68)

0.7

BMI (kg/m2)
(mean ± SD)

28.31 ± 1.9

24.3 ± .39

.004

Whites

13(68)

14(74)

0.72

Others

6(32)

5(26)

Race
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Most patients had STEMI (89%), the mean troponin level was 30.07 ng/mL and
most patients (63%) had a single vessel disease. Full clinical characteristics of
patients are shown in Table 2.
Table2. Clinical characteristics of patients
Characteristic

N(%)

Alcohol use

7(37)

Tobacco use
Current smoker
Ex-smoker
Non-smoker

4(21)
4(21)
11(58)

Past Medical History
Family history of CAD1

13(68)

Diabetes Mellitus Type II

4(21)

Hypertension

6(32)

Prior ACS2

2(10)

Admission diagnoses
STEMI3
NSTEMI4

17(89)
2 (10)

Intervention
Coronary angiography with PCI5
Stent placement

19(100)
18(95)

Number of affected vessels
One-vessel disease
Two-vessel disease
Three-vessel disease

12(63)
6 (32)
1 (5)
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Table 2. (cont.)
Mean Troponin level

30.07 ng/mL

1.Coronary artery disease 2. Acute coronary syndrome 3. ST-segment elevation myocardial
infarction 4. Non-ST segment myocardial infarction 5. Percutaneous coronary intervention.

Intestinal Microbiome
Deep sequencing (minimum sequence count of 37971) of fecal samples revealed
more than one thousand bacterial species. Bacteria with at least 97% similarity in
16S rRNA gene were assigned a unique Operational Taxonomic Unit (OTU).

Alpha Diversity
Number of OTUs
We sequenced all samples to detect all available OTUs as shown in the
observed-OTUs rarefaction plot (figure 2A, B). Rarefaction plot is a marker of
sample richness, in figure 2A, all sample curves reach a plateau, which indicates
that no more OTUs can be found with further sequencing. The OTUs rarefaction
plot are displayed per group in figure 2B.
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A

22

B

Figure 2. Observed OTUs. (A) rarefaction plot of number of OTUs per sample. (B) rarefaction plot
showing number of OTUs per group.
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In both groups, the number of observed OTUs (mean +/- SD) was more than
1000 (1928.9 ± 1165.1 vs 1336.2 ± 611.7, P-value = 0.19), more variability is
noted in the ACS patient group (figure 3).

Figure 3. Number of observed OTUs per group.

Phylogenic Diversity
Phylogenic diversity (PD) is an indicator of biodiversity, PD is measured by
adding the branch lengths of a phylogenetic tree to quantify diversity of a sample
(48). PD was measured for all samples (figure 4A). Our results showed no
significant difference in PD between the two groups: mean PD +/- SD in ACS
patients vs healthy controls was 111.63 ± 45.65 vs 86.55 ± 25.69, P-value =
0.16. (figure 4B).
24
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Figure 4. Phylogenic diversity. (A) rarefaction plot of phylogenic diversity (per subject). (B)
Phylogenic diversity per group.

Chao1 Index
The Chao1 index; a measure of sample richness was performed for all subjects
(figure5A). The Chao1 index was similar in ACS patients and healthy controls:
mean Chao1 index was 3303.3 ± 1747.6 vs 2415.8 ± 977.7, P-value = 0.2,
(figure 5B).
A
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B

Figure 5. Chao1 index. (A) rarefaction plot of Chao1 index per subject. (B) Chao 1 index per
group.

Beta diversity
This is a measure of diversity between different samples.

Unique Fraction Distance (Unifrac)
The unique fraction (unifrac) distance (weighted for abundance) was uniform; a
mean distance of ~ 0.4 was noted between samples within the same group and
between samples within different groups. A Unifrac distance between group one
and group two is defined as the fraction of branches of the phylogenetic tree that
lead to members of either group, but not group one and group two (49) [figure 6].
27

Figure 6. Weighted unique fraction group distances.
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Principal Component Analysis
Principal Component analysis (PCoA) of Unifrac distance showed similar
distribution of ACS and healthy subjects along the three PC axes; no distinct
group clustering was noted (figure 7).

Figure 7. Principal component analysis of weighted unique fraction distance.
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Taxonomic Summaries
Bacterial Phyla
16S rRNA analysis revealed the relative abundance of intestinal major bacterial
phyla in individual subjects, we compared the levels between ACS patients and
healthy controls. Both groups had Bacteroidetes and Firmicutes as the two major
phyla, and a small percentage of Proteobacteria and Actinobacteria, as expected
from prior studies (Figure 8 A, B).
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A

31

B

Figure 8. Bacterial phyla. (A) relative abundance of bacterial phyla per group. (B) relative
abundance of bacterial phyla per subject.

The mean relative abundance of the Phylum, Proteobacteria; Class,
Gammaproteobacteria and Family, Enterobacteriaceae was higher in ACS
patients compared to controls. This was statistically significant only at the
Gammaproteobacteria level (figure 9A-D).
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A

B

Controls

Patients
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C

Patients

Controls

D
P=.056

P=.04

P=.07

Figure 9. Levels of Proteobacteria Gammaproteobacteria and Enterobacteriaceae. (A) mean
percentage of fecal Proteobacteria in ACS patients compared to healthy controls. (B) mean
percentage of fecal Gammaproteobacteria in ACS patients compared to healthy controls. (C)
mean percentage of fecal Enterobacteriacaea in ACS patients compared to healthy controls. (D)
summary of Proteobacteria, Gammaproteobacteria and Enterobacteriaceae levels.
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The other major bacterial phyla were similar between the two groups as shown in
figure 10A-D.
A

Patients

Controls

B
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C

Patients

Controls

D
P=0.6

P=0.5

P=0.4

Figure 10. Bacteroidetes, Firmicutes and Actinobacteria (A) mean percentage of fecal
Bacteroidetes in ACS patients compared to healthy controls. (B) mean percentage of fecal
Firmicutes in ACS patients compared to healthy controls. (C) mean percentage of fecal
Actinobacteria in ACS patients compared to healthy controls. (D) summary of Bacteroidetes,
Firmicutes and Actinobacteria.
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Bacterial Genera
Relative abundance of different bacterial OTUs was calculated in ACS patients
and healthy controls, and in individual subjects. A specific OTU infers specific
bacterial genus (not adequate to identify a specific species or strain) (figure 11A,
B), for legend see supplementary figure1.

A
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B

Figure 11. Bacterial genera. (A) relative abundance of bacteria per group (genus level). (B)
relative abundance of bacteria per subject (genus level).

More than twenty bacterial genera had more than 2-fold difference between the
two groups, a summary is shown in table 3.
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Table 3. Bacterial genera with more than 2-fold difference between the two
groups. Red color indicates higher abundance
Bacterial genera
Methanobrevibacter
Bifidobacterium
Coriobacteriaceae
Bacteroidales
Rikenellaceae;
Odoribacter
Paraprevotellaceae
Paraprevotella
Prevotella
Enterococcus
Lactobacillus
Christensenellaceae
Lachnobacterium
Roseburia
Acidaminococcus
Dialister
Megamonas
Megasphaera
Veillonella
Erysipelotrichaceae
[Eubacterium]
Bilophila
Desulfovibrio
Succinivibrio
Akkermansia

Healthy controls

ACS patients

0.1
1.1
0.1
0.5
0.7
0.2
0.1
1
0
0.1
0.1
0.3
0
0.2
0
0.7
0
0
0.1
0.6
0.1
0.1
0.2
0
2

0.2
0.6
0.4
0.1
1.4
0.6
0.4
0.4
0.3
0
0.4
0.1
0.2
0.4
0.2
1.4
0.2
0.1
0
0.3
0.3
0.3
0.4
0.3
0.6

Intestinal Permeability Test
The lactulose-to-mannitol ratio (L/M ratio) was calculated by dividing the
fractional (percentage) of urinary excretion of lactulose over the fractional
excretion of mannitol. Fifty percent of patients (n=8) and most controls (n=16)
completed the L/M permeability test. The L/M ratio was three times higher in ACS
patients (figure 12A, B).
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A

B

Controls

Patients

P= 0.01

Figure 12. Lactulose-to-mannitol ratio (L/M ratio). (A) L/M ratio in ACS patients and healthy
controls. (B) mean L/M ratio in ACS patients versus controls.
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Lipopolysaccharides; Endotoxin Levels
The mean serum LPS level was less than 1 ng/ml in both groups (figure
13).

Figure 13. Mean serum LPS level in ACS patients compared to healthy controls

Trimethylamine-N-Oxide (TMAO)
TMAO was detected in blood samples from all subjects. No difference in
the TMAO level was detected between the two groups (figure 14).
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Controls

Patients

Figure 14. Mean serum TMAO level in ACS patients and healthy controls.

Results Summary
All major results for both groups are summarized in table 4.
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Table 4. Major test results for patients and controls
Test result

ACS patients

Healthy controls

P-value

(n=18)

(n=18)

Proteobacteria (% ± SD)

4.1 ± 3.8

2.1 ± 1.7

.056

Gammaproteobacteria (% ±

1.8 ± 3.0

0.2 ± 0.4

.04

1.5 ± 2.9

0.2 ± 0.4

.07

Bacteroidetes (%± SD)

36 ± 19

32 ± 17

0.6

Fermicutes (%± SD)

57 ± 19

60 ± 17

0.5

Actinobacteria (%± SD)

1.4 ± 1.5

1.8 ± 1.8

0.4

LPS1 (ng/mL ± SD)

1.01 ± 0.5

1.12 ± 0.35

0.9

L/M2 ratio (± SD)3

.06 ± .07

.023 +/- .02

.014

TMAO4 (uM ± SD)

5.8 ± 4.8

5 ± 2.9

0.5

SD)
Enterobacteriaceae (% ±
SD)

1.Lipopolysaccharide (endotoxin). 2.Lactulose-to-mannitol ratio. 3. Only 8 patients completed this
test along with 16 healthy controls. 4. Trimethylamine-N-Oxide.
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Chapter Four
Discussion
Summary and Discussion of the Results
We found that patients with acute cardiac events (ACS) have a nine-fold increase
in intestinal Gammaproteobacteria (this Class includes opportunistic pathogenic
Gram-negative bacteria); compared to healthy controls. Proteobacteria level was
2-folds higher in ACS patients, but didn’t reach statistical significance (P=0.056).
The Proteobacteria (facultative anaerobes) level detected in stool samples
(luminal fraction) is expected to be much lower than what is actually present on
the mucosal surface of distal intestine (mucosa-associated fraction) (50). ACS
patients have clear dysbiosis compared to healthy controls; up to 72 hours after
an acute cardiac event. After delayed IRB approval, we performed the intestinal
permeability test--lactulose-to-mannitol fractional excretion ratio (L/M ratio) -- in
50% of ACS patients (n=8), and in most healthy controls (n=16). The L/M ratio
was three times higher in patients compared to controls; L/M ratio was 0.06 ± .07
vs 0.02 ± .02, P=0.014. The levels of serum endotoxins
(lipopolysaccharides/LPS) and Trimethylamine-N-Oxide (TMAO) were similar in
both groups, this was unexpected given the significant dysbiosis and the higher
relative abundance of Gammaproteobacteria in the ACS group.
Proteobacteria contributes the most in the variation of the human intestinal
microbiome genome function; a study combined human stool metagenomic data
(from healthy participants) from North America, China and Europe; the mean
Proteobacteria abundance was 1%--much lower than Bacteroidetes and
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Firmicutes-- however, it explained the most variation in gene families of the
intestinal microbiome (51). Intestinal Proteobacteria is the most unstable of the
four-major intestinal bacterial phyla [Bacteroidetes, Firmicutes, Actinobacteria
and Proteobacteria] (52). It is not surprising that high levels of Proteobacteria is a
key feature of dysbiosis in many inflammatory and metabolic conditions (53). For
examples, Proteobacteria is more abundant in Inflammatory bowel disease (IBD)
patients. Furthermore, dysbiosis with alteration in Proteobacteria;
Enterobacteriaceae and E-coli differentiates Non-Alcoholic Steatohepatitis
(NASH) from obesity-associated intestinal microbiome in the absence of NASH
(54). Some studies showed negative correlation between Proteobacteria and
Diabetes Miletus type II (DMII) (55), however, other studies showed that DMII
patients have higher abundance of the Class Betaproteobacteria; not
Gammaproteobacteria (56, 57). A recent study on atherosclerotic cardiovascular
disease (218 patients) showed increased Enterobacteriaceae (a major Family
within the Class Gammaproteobacteria) compared to controls (58).
Our study explored the intestinal microbiome in the setting of acute coronary
syndrome; we studied dysbiosis and related intestinal barrier function, endotoxin
and TMAO levels shortly after subjects had an acute cardiac event, with a goal to
find associations between the study end points and acute cardiac events; and to
understand what makes an atherosclerotic plaque vulnerable. There is a key role
for inflammation and activation of immune cells inside the atherosclerotic plaques
and rupture of the fibrous cap (59), with subsequent clot formation; leading to
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myocardial ischemia/infarction during acute cardiac events. Endotoxins bind to
Toll-like receptor 4 (TLR4) which is present in many cell types including
endothelial cells and macrophages (foam cells inside atherosclerotic plaques)
(31), studying the role of endotoxins in plaque vulnerability is intuitive. Previous
studies confirmed clear correlations between dysbiosis, higher levels of
endotoxins/TMAO and developing a future cardiovascular event, but such data
are scarce for patients during acute cardiac events. We showed an increase in
Gammaproteobacteria in ACS patients but that was not associated with
increased serum endotoxin levels. Gram-negative bacteria produce different
endotoxins—with major variation in the immunogenic Lipid A portion—that bind
to TLR4. Endotoxins (with different lipid A) activate innate immune system and
trigger a largely variable immunogenic response (60, 61). The determination of
different types of endotoxins present in the ACS patients was beyond the scope
of this study. We found no difference in TMAO levels between the two groups,
this result is consistent with a recent study in patients with acute stroke and
Transient Ischemic Attacks [TIAs] (62); patients had lower levels of TMAO
compared to controls. This doesn’t contradict the previous large studies showing
increased risk of acute cardiac events in subjects with high levels of TMAO; it is
possible that TMAO is associated with a long-term risk of cardiovascular
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events—and levels at the time of the event can be normal or low. In addition,
TMAO levels are known to fluctuate widely overtime; over the course of one-year
TMAO levels correlated only weakly (R2=0.29, P= .003) in the same subjects
(63).

Strengths and Limitations

Strengths
This study has multiple strengths; we enrolled patients with a clear-cut diagnosis
of acute coronary syndrome. All patients had an acute event and underwent
percutaneous coronary intervention (PCI) for STEMI (n=17) or NSTEMI(n=2), the
mean troponin I level of 30.07 ng/ml. The majority of patients (89%) had their first
episode of ACS and had no prior stroke or cardiac event. Our study examined
the microbiome composition and dysbiosis in ACS patients, along with studying
the intestinal barrier function and a microbiome originated antigen (LPS) and
metabolite (TMAO).
Limitations
Our study is not short of limitations, ACS patients had higher BMI compared to
healthy controls, we performed a subgroup analysis and our results were not
different when measured in patients with normal BMI (data not shown). We
enrolled patients and obtained samples within 72 hours of the ACS events.
Microbiome composition changes rapidly and changes can be noticed within 2448 hours after hospitalization. Patient enrollment within few hours after going
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through a major health event is difficult; especially when they go through a PCI
procedure. A prior study enrolled stroke patient within 48 hours of the event.
Subgroup analysis of patients enrolled with in the first 24 hours was not different
in microbiome composition from patients enrolled after 24-48 hours (62). Our
patients were mainly recruited, and samples obtained within 48 hours of the
event (89% of cases).
Only 50% of our patients completed the intestinal permeability test due to
delayed IRB approval. The results should be interpreted with caution due to the
small sample size. Compared to a prior alcoholic hepatitis study (performed in
our Digestive Disease Center); L/M ratio in healthy controls was similar (.02 ±
.003). However, the L/M ratio in alcoholic hepatitis was greater than ACS patients
(0.2 ± .08). We think that ACS patients have true increase in L/M ratio, however,
it’s unclear if this is due to the cardiac event and norepinephrine surge or was
present at baseline and contributed to the event.
Future Directions
A study at a larger scale is required to examine the role of the intestinal
permeability in ACS. In microbiome studies, it is important to understand
dysbiosis and the microbiome composition in different disease conditions “who’s
there?”. However, it is more important to understand what is the function of the
bacteria, which enzymatic pathways are activated and what metabolites are
produced “What they’re doing?”. Metagenomic microbiome studies such as LPS
biosynthetic pathway will be helpful, as there is a great variation in the genes
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responsible for LPS production. Metatranscriptomic studies will put greater
insight on the potential function of the microbiome and interactions with the host.
Internal sampling of the ruptured plaque is challenging, but it is possible to
examine the PCI instruments to have a closer look at the bacterial antigens insitu. Future study looking at causality of the microbiome in ACS are prudent. This
will open the door for interventional studies targeting the microbiome function.
Targets for microbiome therapy includes probiotics and prebiotics to alter
enzymatic pathways affecting metabolite production, tightening of the intestinal
TJ barrier, modifying the microbiome with short chain fatty acids, bile salts, and
bacterial antigens and enzymes.
Conclusion
Dysbiosis affects patients with ACS, with an increase in intestinal permeability.
Further studies are required to find the role of dysbiosis in plaque vulnerability
(biomarkers for plaque vulnerability) and to examine if the dysbiosis and leaky
gut are mere associations, or key contributing factors in acute cardiac events.
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